Literature DB >> 7576331

Use of pooling and outpatient laboratory specimens in an anonymous seroprevalence survey of HIV infection in British Columbia, Canada.

C H Sherlock1, S A Strathdee, T Le, D Sutherland, M V O'Shaughnessy, M T Schechter.   

Abstract

OBJECTIVE: To conduct an anonymous HIV seroprevalence survey to establish a baseline estimate of HIV seroprevalence in a general population; to evaluate serum pooling and alternative testing strategies as cost-saving measures.
DESIGN: Prospective anonymous HIV seroprevalence study using outpatient laboratory specimens.
SETTING: Two large non-hospital-associated outpatient chemistry testing laboratories in the major population centers in British Columbia, Canada. PATIENTS AND SERA: Leftover sera received for chemistry screen testing in outpatient laboratories were provided to the study after chemistry testing was completed. Those from patients aged < 15 and > or = 55 years were excluded.
METHODS: Patient identifiers were erased from samples. Sera were pooled 10:1 and tested by viral lysate enzyme-linked immunosorbent assay (ELISA). Sera from HIV-positive pools were tested individually. All individual HIV-positive specimens were retested for verification of positivity using a recombinant protein ELISA. MAIN OUTCOME MEASURES: HIV seroprevalence rates were stratified by sex, age group, and geographic area; and costs of pooling and alternative algorithm strategy were compared with those of conventional methods.
RESULTS: A total of 80,238 sera were collected from 66,658 individuals (53% women, 47% men). Of these, 276 men (88.3 per 10,000) and 24 women (6.8 per 10,000) were HIV-seropositive. The highest rates were in those aged 30-34 years, for both men and women. Using pooling and non-Western blot verification saved US$2.07 per specimen, or 80% of the cost for conventional testing.
CONCLUSIONS: The anonymous outpatient laboratory setting is practicable to obtain a reasonable estimate of HIV seroprevalence rates in a general population. Such studies can be made cost-effective by pooling sera and using alternative confirmatory strategies.

Entities:  

Mesh:

Year:  1995        PMID: 7576331     DOI: 10.1097/00002030-199508000-00017

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Can pooling be used for seroprevalence studies of hepatitis C?

Authors:  G M Stephens; J M Raboud; L Karakas; C H Sherlock
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

2.  Pooling cervical swabs and testing by ligase chain reaction are accurate and cost-saving strategies for diagnosis of Chlamydia trachomatis.

Authors:  J Kapala; D Copes; A Sproston; J Patel; D Jang; A Petrich; J Mahony; K Biers; M Chernesky
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 3.  The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases.

Authors:  Sarah E Wilson; Shelley L Deeks; Todd F Hatchette; Natasha S Crowcroft
Journal:  CMAJ       Date:  2011-11-14       Impact factor: 8.262

4.  Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2.

Authors:  P A Morandi; G A Schockmel; S Yerly; P Burgisser; P Erb; L Matter; R Sitavanc; L Perrin
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

5.  What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response.

Authors:  Steffanie A Strathdee; Natasha K Martin; Eileen V Pitpitan; Jamila K Stockman; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2021-01-01       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.